9 reasons to use eplerenon Review article
Article Sidebar
Main Article Content
Abstract
Treatment with a mineralocorticoid receptor antagonist – spironolactone or eplerenone – is indicated to reduce the risk of hospital admission and death in patients with symptomatic heart failure and reduced left ventricular ejection fraction. Patients treated with eplerenone, better tolerated, more selective mineralocorticoid receptor antagonist, presented significantly lower risk of side effects than patients treated with spironolactone. Eplerenone is the preferred choice especially for patients developing androgenic side effects like breast tenderness, gynecomastia/mastodynia, and/or sexual dysfunction. Eplerenon seems to have several other pleiotropic effects that confer cardioprotection and renoprotection beyond their main treatment effect.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Raport Niewydolność serca w Polsce. Realia, koszty, sugestie poprawy sytuacji. INNOWO 2021.
3. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42: 3599-726.
4. Szymański F, Filipiak K, Mamcarz A et al. Eplerenon w codziennej praktyce – aktualne miejsce w terapii i perspektywy stosowania w Polsce. Stanowisko ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Folia Cardiologica. 2015; 10: 288-93.
5. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21.
6. Zannad F, McMurray JJ, Krum H et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364: 11-21.